Clinical Takeaway
Cannabis use for anxiety produces measurable daily reductions, but the magnitude and pattern of relief differ depending on whether someone uses flower or edible products. CBD-containing products showed anxiolytic effects, while high-THC products had a more variable relationship with anxiety over time. Patients should be counseled that product type and cannabinoid ratio meaningfully influence outcomes when using cannabis to manage anxiety.
#8 Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.
Citation: Rosa Luiza et al.. Therapeutically Motivated Cannabis Use for Anxiety: Daily and Longitudinal Reductions Vary Between Flower and Edible Products.. International journal of environmental research and public health. 2026. PMID: 41752306.
Design: 5 Journal: 0 N: 2 Recency: 3 Pop: 2 Human: 1 Risk: -2
This study clarifies the differential clinical efficacy of cannabis formulations for anxiety management by demonstrating that flower and edible products produce distinct daily and longitudinal anxiety outcomes in real-world use conditions. Understanding these product-specific effects is essential for clinicians counseling patients on cannabis for anxiety, as current evidence conflates formulation types despite their differing pharmacokinetic profiles and THC/CBD ratios. The longitudinal design capturing daily symptom trajectories provides evidence grounded in actual therapeutic use patterns rather than controlled laboratory conditions, improving clinical applicability for anxiety disorder management.
Quality Gate Alerts:
- Preclinical only
Abstract: Research shows that delta-9-tetrahydrocannabinol (THC) is linked to increased anxiety, while cannabidiol (CBD) may have anxiolytic effects. Cannabis use is often driven by coping with anxiety, though its daily impact on anxiety remains unclear. This study examined daily associations between cannabis use and anxiety across 30 days in adults who wanted to use cannabis for anxiety relief. Participants (N = 345) used flower or edible products ad libitum and were randomly assigned to groups by product type (CBD, THC, or THC + CBD). Each day, participants reported cannabis use in the past 24 h and rated their anxiety. Linear mixed-effects models tested whether anxiety changed over time, differed by cannabinoid group, and varied with use. Anxiety significantly decreased over the study period in both flower and edibles groups. In the flower group, THC + CBD and CBD products had greater decreases in anxiety (39.5% and 34.8%, respectively) compared to THC products (7.8%). In the edibles group, when participants used CBD products, this was associated with a 24.9% reduction in anxiety over the 30 days. Findings underscore the importance of distinguishing cannabis effects by product type and cannabinoid composition and suggest that CBD-dominant edibles were associated with less anxiety over time in this naturalistic study.
🧠 This longitudinal study contributes useful real-world data on cannabis product form and anxiety outcomes, yet several limitations warrant cautious interpretation in clinical practice. The study’s strength lies in its daily assessment design and large sample size, but the self-selected population of individuals motivated to use cannabis for anxiety introduces selection bias that likely skews results toward positive outcomes, and the ad libitum dosing means we cannot determine optimal therapeutic windows or account for individual variation in THC/CBD ratios that patients actually consumed. The finding that flower and edible products may differ in their anxiety trajectory is intriguing but requires replication, as differences could reflect cannabinoid content, absorption kinetics, expectancy effects, or unmeasured behavioral factors rather than product form alone. When counseling patients about cannabis for anxiety, clinicians should emphasize that while some individuals report benefit, THC’s anxiogenic potential and risk of dependence remain serious concerns, and this study cannot establish causation or rule out placebo effects or concurrent lifestyle changes. A practical approach is to
| |